Manish Kohli,
MD
No Rating Available?
0
out of
5
Patient Rating
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the
minimum.
Languages Spoken: English
Dr. Manish Kohli graduated in 1990 from the University of Delhi with an Internal Medicine residency training at Cook County Hospital, Chicago from 1993-1996. After completing a 3-year Fellowship in Hematology-Oncology at the University of Arkansas from 1996-99, he joined the Central Arkansas Veteran HealthCare System in Little Rock as Staff physician with a joint appointment at the University of Arkansas for Medical Sciences (UAMS) as Assistant Professor of Medicine. During this time Dr. Kohli authored/co-authored several critical research trials including SWOG-9916, which introduced docetaxel chemotherapy in metastatic castrate resistant stage. In 2005, he joined University of Rochester, New York at the rank of Associate Professor in Medicine in which he oversaw critical areas of genomic and liquid biopsy based research. In June 2008, Dr. Kohli joined Mayo Clinic, Rochester, taking charge to build a comprehensive Genitourinary Oncology translational and clinical research program and was promoted to Consultant/Professor in 2016 in the Department of Oncology. In 2018, he was appointed Vice-Chair of the Department of Genitourinary Oncology and as a Distinguished Moffitt Scholar at the Moffitt Cancer Center, Tampa, also appointed as the Director of the DeBartolo Family Personalized Medicine Institute. He joined Huntsman Cancer Institute-University of Utah in January 2020 as a Presidential Endowed Chair and Professor. Dr. Kohli also holds an Adjunct Faculty rank at the University of Illinois in Urbana Champagne where he works with colleagues on two different RO1s for ultrasensitive liquid biopsy profiling of molecular determinants of a variety of clinical outcomes. His research in advanced prostate cancer focusses on “convergence sciences” which combines population based trials with precision medicine concepts.
Clinical Locations
Clinic 2B, GU
801-587-4644
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) |
Dr. Manish Kohli graduated in 1990 from the University of Delhi with an Internal Medicine residency training at Cook County Hospital, Chicago from 1993-1996. After completing a 3-year Fellowship in Hematology-Oncology at the University of Arkansas from 1996-99, he joined the Central Arkansas Veteran HealthCare System in Little Rock as Staff physician with a joint appointment at the University of Arkansas for Medical Sciences (UAMS) as Assistant Professor of Medicine. During this time Dr. Kohli authored/co-authored several critical research trials including SWOG-9916, which introduced docetaxel chemotherapy in metastatic castrate resistant stage. In 2005, he joined University of Rochester, New York at the rank of Associate Professor in Medicine in which he oversaw critical areas of genomic and liquid biopsy based research. In June 2008, Dr. Kohli joined Mayo Clinic, Rochester, taking charge to build a comprehensive Genitourinary Oncology translational and clinical research program and was promoted to Consultant/Professor in 2016 in the Department of Oncology. In 2018, he was appointed Vice-Chair of the Department of Genitourinary Oncology and as a Distinguished Moffitt Scholar at the Moffitt Cancer Center, Tampa, also appointed as the Director of the DeBartolo Family Personalized Medicine Institute. He joined Huntsman Cancer Institute-University of Utah in January 2020 as a Presidential Endowed Chair and Professor. Dr. Kohli also holds an Adjunct Faculty rank at the University of Illinois in Urbana Champagne where he works with colleagues on two different RO1s for ultrasensitive liquid biopsy profiling of molecular determinants of a variety of clinical outcomes. His research in advanced prostate cancer focusses on “convergence sciences” which combines population based trials with precision medicine concepts.
Academic Locations
Primary Children’s and Families’ Cancer Research Center
801-585-0255
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) |
Research Interests
- Genomic and Liquid Biopsy Research
- Genitourinary Cancers
Education History
| Certification | Harvard Medical School Global Clinical Scholars Research Training Program; Clinical Trials Concentration Certificate, 2015 |
| Fellowship | University of Arkansas for Medical Sciences Hematology/Oncology Fellow, 1999 |
| Residency | Cook County Hospital Internal Medicine Resident, 1996 |
| Professional Medical | Maulana Azad Medical College, University of Delhi Medicine/Surgery M.B.B.S., 1990 |
Selected Publications - Journal Articles
Journal Article
- Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. (Epub ahead of print) Oncologist.
- Sun L, Du M, Kohli M, Huang CC, Chen X, Xu M, Shen H, Wang S, Wang L (2021). An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma. Front Oncol, 11, 691798.
- Riaz IB, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi SAA, Warner JL, Murad MH, Kohli M (2021). Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clin Cancer Inform, 5, 588-599.
- Kwan EM, Dai C, Fettke H, Hauser C, Docanto MM, Bukczynska P, Ng N, Foroughi S, Graham LK, Mahon K, Tan W, Wang X, Zhao Z, Zheng T, Zhou K, Yu J, Du P, Horvath LG, Jia S, Kohli M, Azad AA (2021). Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, (5), 622-637.
- Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, Mahon KL, Mak B, Sutherland PD, Shepherd A, Mellett N, Docanto M, Giles C, Centenera MM, Butler LM, Meikle PJ, Horvath LG (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. (Epub ahead of print) Prostate Cancer Prostatic Dis.
- Bhawal R, Oberg AL, Zhang S, Kohli M (2020). Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer. Cancers (Basel), 12(9).
- Fettke H, Kwan EM, Docanto MM, Bukczynska P, Ng N, Graham LK, Mahon K, Hauser C, Tan W, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Huang Y, Jia S, Kohli M, Horvath LG, Azad AA (2020). Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol, 78(2), 173-180.
- Du M, Huang CC, Tan W, Kohli M, Wang L (2020). Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel), 12(8).
- Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA (2020). Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine, 54, 102728.
- Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M (2020). Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. (Epub ahead of print) Prostate Cancer Prostatic Dis.
- Smith LD, Liu Y, Zahid MU, Canady TD, Wang L, Kohli M, Cunningham BT, Smith AM (2020). High-Fidelity Single Molecule Quantification in a Flow Cytometer Using Multiparametric Optical Analysis. ACS Nano, 14(2), 2324-2335.
- Zhu J, Huang J, Zhang P, Li Q, Kohli M, Huang CC, Wang L (2019). Advantages of Single-Stranded DNA Over Double-Stranded DNA Library Preparation for Capturing Cell-Free Tumor DNA in Plasma. Mol Diagn Ther, 24(1), 95-101.
- You B, Mercier F, Assenat E, Langlois-Jacques C, Glehen O, Soul J, Payen L, Kepenekian V, Dupuy M, Belouin F, Morency E, Saywell V, Flacelire M, Elies P, Liaud P, Mazard T, Maucort-Boulch D, Tan W, Vire B, Villeneuve L, Ychou M, Kohli M, Joubert D, Prieur A (2019). The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine, 51, 102574.
- Canady TD, Li N, Smith LD, Lu Y, Kohli M, Smith AM, Cunningham BT (2019). Digital-resolution detection of microRNA with single-base selectivity by photonic resonator absorption microscopy. Proc Natl Acad Sci U S A, 116(39), 19362-19367.
- Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, Na J, Polley EC, Couch FJ, Kohli M (2019). Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. JCO Precis Oncol, 3.
- Kohli M, Oberg AL, Mahoney DW, Riska SM, Sherwood R, Zhang Y, Zenka RM, Sahasrabudhe D, Qin R, Zhang S (2019). Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer. Clin Genitourin Cancer, 17(4), 248-253.e7.
- Riaz IB, Faridi W, Husnain M, Malik SU, Sipra QUAR, Gondal FR, Xie H, Yadav S, Kohli M (2019). Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis. Mayo Clin Proc, 94(8), 1524-1534.
- Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, Sinnwell JP, Eiken PW, McMenomy BP, Tan W, Wang L, Carlson RE, Kohli M (2019). A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clin Proc Innov Qual Outcomes, 3(1), 14-22.
- Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, Cheung M, Best R, Cheung D, Huang R, Barros-Gomes S, Pitz M, Singal PK, Jassal DS, Mulvagh SL (2018). Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr, 32(2), 267-276.
- Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H (2018). Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Mol Cell, 73(1), 22-35.e6.
- Riaz IB, Wang L, Kohli M (2018). Liquid biopsy approach in the management of prostate cancer. Transl Res, 201, 60-70.
- Smith L, Kohli M, Smith AM (2018). Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration. J Am Chem Soc, 140(42), 13904-13912.
- Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H (2018). TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer. Clin Cancer Res, 24(18), 4551-4565.
- Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M (2018). Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 21(3), 431-437.
- Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L (2018). Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis, 21(3), 411-418.
- Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L (2017). TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacol Ther, 104(1), 201-210.
- Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C (2018). Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol, 73(6), 847-855.
- Zhang P, Xia JH, Zhu J, Gao P, Tian YJ, Du M, Guo YC, Suleman S, Zhang Q, Kohli M, Tillmans LS, Thibodeau SN, French AJ, Cerhan JR, Wang LD, Wei GH, Wang L (2018). High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat Commun, 9(1), 2022.
- Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ (2018). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol, 36(11), 1080-1087.
- He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H (2017). Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Res, 46(4), 1895-1911.
- Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W (2017). PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res, 24(4), 834-846.
- Sanhueza C, Kohli M (2018). Clinical and Novel Biomarkers in the Management of Prostate Cancer. Curr Treat Options Oncol, 19(2), 8.
- Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M (2017). A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol, 29(2), 352-360.
- Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M (2017). Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int J Mol Sci, 18(11).
- Giridhar KV, Kohli M (2017). Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clin Proc, 92(10), 1564-1582.
- Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM (2017). Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res, 23(16), 4704-4715.
- Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L (2017). Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Canc Res, 29(4), 374-378.
- Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L (2017). Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget, 8(38), 63703-63714.
- Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, Cerhan JR, Kohli M (2016). Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int, 119(3), 489-495.
- Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L (2016). miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer, 15(1), 70.
- Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N (2016). HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol, 17(10), 1435-1444.
- Shenoy N, Kohli M (2016). Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol, 32(4), 257-261.
- Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M (2016). Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci, 17(7).
- Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H (2015). Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget, 7(25), 38551-38565.
- Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M (2015). Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget, 7(24), 35818-35831.
- Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS (2016). Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 387(10032), 2008-16.
- Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN (2016). Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol, 34(13), 1500-9.
- Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H (2016). Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep, 15(3), 599-610.
- Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M (2016). Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open, 6(4), e010332.
- Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JP (2016). Measure transcript integrity using RNA-seq data. BMC Bioinformatics, 17, 58.
- Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L (2016). Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep, 6, 19413.
- Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z (2015). Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate, 76(1), 48-57.
- Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L (2015). Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS ONE, 10(12), e0145176.
- Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373(8), 737-46.
- Bordun KA, Premecz S, daSilva M, Mandal S, Goyal V, Glavinovic T, Cheung M, Cheung D, White CW, Chaudhary R, Freed DH, Villarraga HR, Herrmann J, Kohli M, Ravandi A, Thliveris J, Pitz M, Singal PK, Mulvagh S, Jassal DS (2015). The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Am J Physiol Heart Circ Physiol, 309(4), H692-701.
- Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV (2015). Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther, 8, 1915-22.
- Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L (2015). Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget, 6(18), 16411-21.
- Thanarajasingam G, Milone M, Kohli M (2015). Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis. BMJ Case Rep, 2015.
- Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L (2014). Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol, 67(1), 33-41.
- Loprinzi PD, Kohli M (2013). Health characteristics and sedentary behavior impact on prostate-specific antigen levels in a national U.S. sample. J Phys Act Health, 11(8), 1587-92.
- Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M (2014). Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc, 89(9), 1287-306.
- Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD (2014). Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol, 192(2), 357-63.
- Vaa B, Kohli M, Price KA, Swetz KM (2014). Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder. BMJ Case Rep, 2014.
- Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV (2014). Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther, 13(5), 1067-77.
- Yuan T, Huang X, Dittmar RL, Du M, Kohli M, Boardman L, Thibodeau SN, Wang L (2014). eRNA: a graphic user interface-based tool optimized for large data analysis from high-throughput RNA sequencing. BMC Genomics, 15, 176.
- Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M (2013). Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 120(5), 692-701.
- Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ (2014). Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget, 5(3), 824-40.
- Ma L, Kohli M, Smith A (2013). Nanoparticles for combination drug therapy. ACS Nano, 7(11), 9518-25.
- Qin R, Kohli M (2018). Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Per Med, 10(8), 859-869.
- Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L (2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 14, 319.
- Loprinzi PD, Kohli M (2012). Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc, 88(1), 11-21.
- Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M (2014). An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens Health, 9(3), 182-189.
- Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC (2011). The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc, 87(6), 540-7.
- Jones JM, Kohli M, Loprinzi CL (2012). Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl, 14(2), 193-7.
- Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR (2011). Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc, 87(3), 240-6.
- Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV (2012). Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med, 2012, 303019.
- Kohli M, Qin R, Jimenez R, Dehm SM (2012). Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol, 2012, 781459.
- Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV (2011). Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J, 13(3), 365-77.
- Block MS, Kohli M (2011). Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol, 9(4), 335-8.
- Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA (2010). Thrombin expression in prostate: a novel finding. Cancer Invest, 29(1), 62-7.
- Kohli M, Tindall DJ (2010). New developments in the medical management of prostate cancer. Mayo Clin Proc, 85(1), 77-86.
- Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D (2010). Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark, 7(2), 101-8.
- Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA (2009). Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest, 27(4), 430-4.
- Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M (2007). Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol, 16(1), 1-6.
- Kohli M, Schaefer R (2005). Management of solitary palatal metastasis from renal cell carcinoma. Nature Clinical Practice Urology, 3(7), 392-6; quiz following 396.
- Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M (2006). Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol, 13(6), 798-800.
- Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2006). Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst, 98(8), 516-21.
- Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P (2005). Thrombin receptor expression is upregulated in prostate cancer. Prostate, 66(3), 273-82.
- Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ (2007). Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark, 2(6), 249-58.
- Challagundla S, Gokden M, Viswamitra S, Kohli M (2005). Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clinical Prostate Cancer, 4(2), 134-7.
- Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M (2005). Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol, 3(5), 425-7.
- Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351(15), 1513-20.
- Kohli M, Zent C, Hutchins LF, Safar M, Dotson P, Mehta P (2004). The academic hematology-oncology firm:a model for postgraduate cancer education. J Cancer Educ, 19(1), 45-9.
- Kohli M, Kaushal V, Mehta P (2003). Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost, 29(3), 301-8.
- Kohli M, Kaushal V, Spencer HJ, Mehta P (2003). Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology, 61(4), 765-9.
- Kaushal V, Kohli M, Mehta P, Mehta JL (2003). Potential anticancer effects of statins: fact or fiction? Endothelium, 10(1), 49-58.
- Kohli M, Fink LM, Spencer HJ, Zent CS (2002). Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis, 13(1), 1-5.
- Kohli M, Schichman SA, Fink L, Zent CS (2000). Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J, 93(5), 469-71.
Case Report
- Zhang B, Malouf J, Young P, Kohli M, Dronca R (2013). Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors, 5(3), e29.
- Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R (2010). Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors, 2(4), e65.
Editorial
- Rajkumar SV, Kohli M (2015). Introduction to the Symposium on Neoplastic Hematology and Medical Oncology. Mayo Clin Proc, 90(7), 848-9.
- Kohli M (2013). Does our "flight and fight" response have a link with cancer? Mayo Clin Proc, 88(11), 1185-7.
Letter
- Kohli M, Loprinzi PD (2013). Serum prostate-specific antigen association with neutrophil counts: results from the National Health and Nutrition Examination Survey 2001-2010. [Letter to the editor]. Int J Urol, 21(2), 224-5.
- Tilburt JC, Kim S, Kohli M, Nahbhan M (2013). In reply. [Letter to the editor]. Mayo Clin Proc, 88(3), 308.
- Kohli S, Kohli M (2006). Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer: are there implications for blood pressure management in patients receiving chemotherapy? [Letter to the editor]. J Clin Oncol, 24(15), 2399; author reply 2399-400.
- Kohli M (2005). Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. [Letter to the editor]. Cancer, 106(1), 234-5; author reply 235.
- Alikhan M, Spencer HJ, Kohli M (2005). High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon. [Letter to the editor]. J Clin Oncol, 23(25), 6267-8; author reply 6268-9.
- Alikhan MA, Phooskooru V, Kohli M (2004). Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. [Letter to the editor]. J Natl Cancer Inst, 96(23), 1794; author reply 1794.
- Kohli M, Khan MA, Mehta P, Hutchins L (2003). Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? [Letter to the editor]. J Clin Oncol, 21(12), 2445.
- Kaushal V, Kohli M, Zangari M, Fink L, Mehta P (2002). Endothelial dysfunction in antiangiogenesis-associated thrombosis. [Letter to the editor]. J Clin Oncol, 20(13), 3042; author reply 3042-3.
Abstract
- McFarland TR, Nussenzveig R, Swami U, Sayegh N, Kessel A, Sharma P, Li H, Kohli M, Maughan BL, Pal SK, Agarwal N (). Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations. Proc Am Soc Clin Oncol, Abst 166. [Abstract].
- Reisinger R, Wesolowski S, Swami U, Barata PC, Hernandez EJ, Nussenzveig R, Lemmon G, Peterson B, Hensel C, Bilen MA, Heath EI, Nandagopal L, Saylor PJ, Babiker HM, Kohli M, Pal SK, Lilly MB, Yandell M, Sartor AO, Agarwal N (). Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA). Proc Am Soc Clin Oncol, Abst 162. [Abstract].
- Kwan EM, Dai C, Fettke H, Hauser C, Bukczynska P, Ng N, Foroughi S, Graham LJK, Mahon KL, Tan W, Wang A, Zhao Z, Zheng T, Zhou K, Yu JJ, Du P, Horvath L, Jia S, Kohli M, Azad A (). Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts. Abst 159 [Abstract].
- Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA (). Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. Proc Am Soc Clin Oncol, Abst 156. [Abstract].
- Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL (). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. Abst 135. [Abstract].
- Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li H, Kohli M, Maughan BL, Goldkorn A, Agarwal N (). Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. Abst 59 [Abstract].